Moustafa MA, Ramdial JL, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, Brooks T, Zain J, Bennani NN, Braunstein Z, Brammer JE, Beitinjaneh A, Jagadeesh D, Weng WK, Kumar A, Kharfan-Dabaja MA, Ahmed S, Murthy HS
BACKGROUND : Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell transplantation (HCT) is limited, as is the choice between autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT) in the treatment of this disease.
OBJECTIVE : To evaluate the outcome of patients with HSTCL who underwent either auto-HCT or allo-HCT.
STUDY DESIGN : We performed a multi-institutional retrospective cohort study to assess outcomes of HCT in HSTCL patients.
RESUTLS : Fifty-three patients with HSTCL were included in the study. Thirty-six patients received an allo-HCT and 17 an auto-HCT. Thirty-five (66%) were males. Median age at diagnosis was 38 (range 2-64) years. Median follow-up for survivors was 75 months (range 8-204). The median number of prior lines of therapy was 1 (range 1-4). Median OS and progression-free survival (PFS) for the entire cohort were 78.5 months (95% CI: 25-79) and 54 months (95% CI: 18-75), respectively. There were no significant differences in OS (HR: 0.63, 95% CI: 0.28-1.45, p=0.245) or PFS (HR: 0.7, 95% CI: 0.32-1.57, p=0.365) between the allo-HCT and auto-HCT groups, respectively. In the allo-HCT group, the 3-year cumulative incidence of relapse was 35% (95% CI: 21-57), while 3-year cumulative incidence of NRM was 16% (95% CI: 7-35). In the auto-HCT group, the 3-year cumulative incidence of relapse and NRM were 43% (95% CI: 23-78) and 14% (95% CI: 4-52), respectively.
CONCLUSION : Both Auto-HCT and Allo-HCT are effective consolidative strategies in patients with HSTCL, and patients should be promptly referred for HCT evaluation.